|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02126 JW THERAP-B
Nominal 
1.330 0.000 (0.000%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 173,856 | 19.323% | 145,702 | 30,797 | 0 | 0 |
| Cost of Sales | (85,637) | -1.506% | (86,946) | (21,752) | -- | -- |
| Gross Profit | 88,219 | 50.145% | 58,756 | 9,045 | -- | -- |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | 51,151 | (1,225,636) | (429,045) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (767,996) | -9.235% | (846,135) | (702,328) | (1,663,803) | (633,257) | |
| Taxation | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (767,996) | -9.235% | (846,135) | (702,328) | (1,663,803) | (633,257) | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (21,611) | 121.697% | (9,748) | (5,604) | (2,671) | (469) |
| Depreciation & Amortisation | 97,604 | 15.085% | 84,810 | 45,648 | 23,590 | 17,303 |
| Directors' Emoluments | 22,797 | -30.878% | 32,981 | 47,163 | 102,732 | 3,660 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -187.000 | -9.223% | -206.000 | -176.000 | -1,261.000 | -974.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | (0.968) | -- | (1.309) | (1.404) | (1.979) | (2.907) |
| NBV per share ($) | 4.083 | -- | 5.728 | 6.847 | 8.842 | -- |
| Remarks: | Real time quote last updated: 19/11/2024 09:48 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -240,267,000 |
| %Change | -36.841% |
| EPS / (LPS) | RMB -0.580 |
| NBV Per Share (¥) | RMB 3.570 |